Levodopa/Carbidopa/Entacapone Teva (Carbidopa, Entacapone, Levodopa)

The combination works by delivering levodopa, which is converted to dopamine in the brain, while carbidopa prevents its breakdown outside the central nervous system, increasing brain availability. Entacapone further inhibits the COMT enzyme, prolonging levodopa's plasma half‑life and enhancing its therapeutic effect.

The specific dose and dosing schedule are determined by the prescribing clinician based on the individual patient's disease stage, response to therapy, and tolerability. Patients should follow the prescriber's instructions and not adjust the dose without medical guidance.

Safety data for use in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with levodopa alone, the addition of carbidopa reduces peripheral side effects and increases central availability, while entacapone extends levodopa's half‑life, offering more stable symptom control. It is often preferred over single‑component regimens for patients experiencing motor fluctuations.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in humid or excessively hot environments to maintain product stability.

Levodopa/Carbidopa/Entacapone is taken orally, usually with a glass of water. It may be taken with or without food, but consistent timing relative to meals can help reduce gastrointestinal side effects. Follow the prescriber's instructions regarding dosing intervals.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations, and severe psychiatric reactions such as psychosis. Patients should be monitored closely for these effects, and any sudden changes in behavior or movement should be reported to a healthcare professional immediately.

Patients with known hypersensitivity to levodopa, carbidopa, entacapone, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors. Caution is advised in patients with severe cardiovascular disease, narrow‑angle glaucoma, or a history of severe psychiatric disorders.